Targets › MER
1 program from 1 company in 2 trials: 2 Phase 1; Oncology, Respiratory; next expected readout Dec 2027.
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). (UniProt, Q12866)
Open in Phaseline: the race on MER, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Qurient | Adrixetinib (Q702) Axl/Mer/CSF1R selective tyrosine kinase inhibitor | AXL, MER, CSF1R | Phase 1 | Esophageal Cancer; Chronic Graft-Versus-Host Disease | Dec 2027 |
Esophageal Cancer (1) Chronic Graft-Versus-Host Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.